This is a summary of two publications. One publication is about the GATHER1 study, which was published in the journal Ophthalmology in 2021. The other publication is about the GATHER2 study, which was published in the journal The Lancet in 2023. Both studies included adult participants with geographic atrophy (GA). GA is an advanced form of dry age-related macular degeneration (dry AMD). The participants in both studies each received treatment in one of their eyes. In both studies, the researchers wanted to learn if avacincaptad pegol (ACP) could help to slow the worsening of the participants’ GA over time.This Plain Language Summary of Publication article (PLSP) from Immunotherapy summarises two studies, GATHER1 (which was published in 2021) and GATHER2 (which was published in 2023). Both studies looked at an advanced form of dry-age related macular degeneration called geographic atrophy (GA). Researchers wanted to learn if a medication called avacincaptad pegol could help slow the worsening of the participants’ GA over time.

Visit the Future Medicine using the link to read the article.

This PLSP is based on two original articles, the first original article on which this summary is based is called ‘C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration’ and was published in the Ophthalmology.

Visit the American Academy of Ophthalmology using the link to read the article.

The second article on which this summary is based is called ‘Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial’ and was published in The Lancet. 

Visit The Lancet using the link to read the article.